RU2001110120A - MODIFIED SIGNAL PEPTIDE ENTEROTOXIN-II E. COLI AND MICROORGANISM EXPRESSING THE Fusion PROTEIN OF THE MENTIONED PEPTIDE WITH A HETEROLOGICAL PROTEIN - Google Patents
MODIFIED SIGNAL PEPTIDE ENTEROTOXIN-II E. COLI AND MICROORGANISM EXPRESSING THE Fusion PROTEIN OF THE MENTIONED PEPTIDE WITH A HETEROLOGICAL PROTEINInfo
- Publication number
- RU2001110120A RU2001110120A RU2001110120/04A RU2001110120A RU2001110120A RU 2001110120 A RU2001110120 A RU 2001110120A RU 2001110120/04 A RU2001110120/04 A RU 2001110120/04A RU 2001110120 A RU2001110120 A RU 2001110120A RU 2001110120 A RU2001110120 A RU 2001110120A
- Authority
- RU
- Russia
- Prior art keywords
- asn
- replaced
- amino acid
- coli
- gln
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title claims 8
- 108090000623 proteins and genes Proteins 0.000 title claims 8
- 244000005700 microbiome Species 0.000 title claims 6
- 230000004927 fusion Effects 0.000 title 1
- 241000588724 Escherichia coli Species 0.000 claims 14
- 150000001413 amino acids Chemical group 0.000 claims 14
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 12
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 11
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 4
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 4
- 125000000267 glycino group Chemical group [H]N([*])C([H])([H])C(=O)O[H] 0.000 claims 3
- 102000002265 Human Growth Hormone Human genes 0.000 claims 2
- 108010000521 Human Growth Hormone Proteins 0.000 claims 2
- 239000000854 Human Growth Hormone Substances 0.000 claims 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 2
- 210000001322 Periplasm Anatomy 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 108020004705 Codon Proteins 0.000 claims 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N L-serine Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 1
- 230000000977 initiatory Effects 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 108091005593 modified peptides Proteins 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
Claims (1)
2. Модифицированный сигнальный пептид энтеротоксина-II E. coli по п. 1, в котором: 2-я аминокислота Lys не заменена; 4-я аминокислота Asn заменена на Ser, Thr, Lys или Gln; 5-я аминокислота Ile не заменена или заменена на Thr или Ser; 12-я аминокислота Met не заменена или заменена на Ala, Gly, Val, Leu или Ile; 20-я аминокислота Asn не заменена или заменена на Ile, Phe, Ala или Val; и 22-я аминокислота Туr не заменена или заменена на Gln, Asn, Ala или Lys.1. Modified E. coli enterotoxin-II signal peptide, characterized in that at least one of the amino acids at positions 2, 4, 5, 12, 20 and 22 of E. coli enterotoxin-II signal peptide with the following amino acid sequence (SEQ ID NO 1) is replaced by another amino acid, provided that at least one of the amino acids in the 2nd and 4th positions of the modified peptide is lysine:
2. The modified E. coli enterotoxin-II signal peptide according to claim 1, wherein: the 2nd amino acid Lys is not replaced; The 4th amino acid Asn is replaced by Ser, Thr, Lys or Gln; The 5th amino acid Ile is not replaced or replaced by Thr or Ser; The 12th amino acid Met is not replaced or replaced by Ala, Gly, Val, Leu or Ile; The 20th amino acid Asn is not replaced or is replaced by Ile, Phe, Ala or Val; and the 22nd amino acid Tur is not replaced or is replaced by Gln, Asn, Ala, or Lys.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1019980038061A KR100316347B1 (en) | 1998-09-15 | 1998-09-15 | Recombinant microorganisms expressing a fusion protein of Escherichia coli enterotoxin II signal peptide and fusion protein of human growth hormone and a method of producing human growth hormone using the same |
| KR1998/38061 | 1998-09-15 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2198179C2 RU2198179C2 (en) | 2003-02-10 |
| RU2001110120A true RU2001110120A (en) | 2003-02-10 |
Family
ID=36120918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2001110120/04A RU2198179C2 (en) | 1998-09-15 | 1999-09-15 | Modified signal peptide of escherichia coli enterotoxin-ii and microorganism expressing fusion protein of mentioned peptide with heterological protein |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US6605697B1 (en) |
| EP (1) | EP1114062B1 (en) |
| JP (1) | JP3701201B2 (en) |
| KR (1) | KR100316347B1 (en) |
| CN (1) | CN1144815C (en) |
| AT (1) | ATE317398T1 (en) |
| AU (1) | AU754435B2 (en) |
| BR (1) | BRPI9913698B1 (en) |
| CA (1) | CA2342537C (en) |
| DE (1) | DE69929805T2 (en) |
| DK (1) | DK1114062T3 (en) |
| NZ (1) | NZ510385A (en) |
| RU (1) | RU2198179C2 (en) |
| WO (1) | WO2000015661A1 (en) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6242177B1 (en) * | 1995-03-01 | 2001-06-05 | Genentech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| KR100356140B1 (en) * | 1999-07-08 | 2002-10-19 | 한미약품공업 주식회사 | Modified Human Granulocyte-Colony Stimulating Factor and Process for Producing Same |
| KR100360594B1 (en) * | 2000-01-19 | 2002-11-13 | 한미약품공업 주식회사 | Expression and secretion vector for human interferon alpha and process for producing human interferon alpha by employing same |
| KR100570422B1 (en) * | 2003-10-16 | 2006-04-11 | 한미약품 주식회사 | Expression vector for secreting an antibody fragment using e. coli signal peptide and method for the mass production of antibody fragment using same |
| US8110665B2 (en) | 2003-11-13 | 2012-02-07 | Hanmi Holdings Co., Ltd. | Pharmaceutical composition comprising an immunoglobulin FC region as a carrier |
| AU2004282984B2 (en) | 2003-11-13 | 2011-07-14 | Hanmi Science Co., Ltd. | Protein complex using immunoglobulin fragment andmethod for the preparation thereof |
| CN101505789A (en) | 2006-07-06 | 2009-08-12 | 株式会社大熊 | A stable liquid formulation of human growth hormone |
| US20080124355A1 (en) | 2006-09-22 | 2008-05-29 | David Gordon Bermudes | Live bacterial vaccines for viral infection prophylaxis or treatment |
| US8241623B1 (en) | 2009-02-09 | 2012-08-14 | David Bermudes | Protease sensitivity expression system |
| US8524220B1 (en) | 2010-02-09 | 2013-09-03 | David Gordon Bermudes | Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria |
| US9597379B1 (en) | 2010-02-09 | 2017-03-21 | David Gordon Bermudes | Protease inhibitor combination with therapeutic proteins including antibodies |
| US8771669B1 (en) | 2010-02-09 | 2014-07-08 | David Gordon Bermudes | Immunization and/or treatment of parasites and infectious agents by live bacteria |
| KR101831300B1 (en) | 2010-10-29 | 2018-02-23 | 한미사이언스 주식회사 | Method of purifying human granulocyte-colony stimulating factor from recombinant e. coli |
| US9593339B1 (en) | 2013-02-14 | 2017-03-14 | David Gordon Bermudes | Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment |
| US9737592B1 (en) | 2014-02-14 | 2017-08-22 | David Gordon Bermudes | Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment |
| WO2017180587A2 (en) | 2016-04-11 | 2017-10-19 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| EA037848B1 (en) | 2016-07-14 | 2021-05-27 | Общество С Ограниченной Ответственностью "Биохимический Агент" | Fusion protein, polynucleotide, genetic construct, producer, preparation for regeneration of cartilage (variants) |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US20220403001A1 (en) | 2018-06-12 | 2022-12-22 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| WO2020086742A1 (en) | 2018-10-24 | 2020-04-30 | Obsidian Therapeutics, Inc. | Er tunable protein regulation |
| AU2020235865A1 (en) | 2019-03-08 | 2021-09-23 | Obsidian Therapeutics, Inc. | Human carbonic anhydrase 2 compositions and methods for tunable regulation |
| US11471497B1 (en) | 2019-03-13 | 2022-10-18 | David Gordon Bermudes | Copper chelation therapeutics |
| WO2020252405A1 (en) | 2019-06-12 | 2020-12-17 | Obsidian Therapeutics, Inc. | Ca2 compositions and methods for tunable regulation |
| WO2020252404A1 (en) | 2019-06-12 | 2020-12-17 | Obsidian Therapeutics, Inc. | Ca2 compositions and methods for tunable regulation |
| US20220348937A1 (en) | 2019-09-06 | 2022-11-03 | Obsidian Therapeutics, Inc. | Compositions and methods for dhfr tunable protein regulation |
| US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
| EP4263588A1 (en) | 2020-12-15 | 2023-10-25 | Arvada Therapeutics, Inc. | Dsg2 compositions and methods for the treatment of covid-19 |
| WO2023081674A1 (en) | 2021-11-02 | 2023-05-11 | Arvada Therapeutics, Inc. | Dsg2 compositions and methods |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3586386T2 (en) * | 1984-10-05 | 1993-01-14 | Genentech Inc | DNA, CELL CULTURES AND METHOD FOR THE SECRETION OF HETEROLOGICAL PROTEINS AND PERIPLASMIC PROTEIN RECOVERY. |
| JPS63230089A (en) * | 1987-03-18 | 1988-09-26 | Takeda Chem Ind Ltd | Production of protein by secretion manifestation |
| JPH0479898A (en) * | 1990-07-23 | 1992-03-13 | Kitasato Inst:The | Dna and rna probe to simultaneously detect vibrio cholerate and enterotoxigenic escherichia coli and detection of vibrio cholera and enterogexigenic escherichia coli using the same dna and rna probe |
| EP0626448A3 (en) * | 1993-05-26 | 1998-01-14 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | Process for preparing and purifying alpha-interferon |
-
1998
- 1998-09-15 KR KR1019980038061A patent/KR100316347B1/en active IP Right Grant
-
1999
- 1999-09-15 DE DE69929805T patent/DE69929805T2/en not_active Expired - Lifetime
- 1999-09-15 CA CA002342537A patent/CA2342537C/en not_active Expired - Lifetime
- 1999-09-15 BR BRPI9913698A patent/BRPI9913698B1/en not_active IP Right Cessation
- 1999-09-15 AU AU57618/99A patent/AU754435B2/en not_active Expired
- 1999-09-15 JP JP2000570199A patent/JP3701201B2/en not_active Expired - Lifetime
- 1999-09-15 AT AT99944889T patent/ATE317398T1/en not_active IP Right Cessation
- 1999-09-15 CN CNB99810924XA patent/CN1144815C/en not_active Expired - Lifetime
- 1999-09-15 DK DK99944889T patent/DK1114062T3/en active
- 1999-09-15 NZ NZ510385A patent/NZ510385A/en not_active IP Right Cessation
- 1999-09-15 WO PCT/KR1999/000547 patent/WO2000015661A1/en active IP Right Grant
- 1999-09-15 US US09/786,569 patent/US6605697B1/en not_active Expired - Lifetime
- 1999-09-15 EP EP99944889A patent/EP1114062B1/en not_active Expired - Lifetime
- 1999-09-15 RU RU2001110120/04A patent/RU2198179C2/en active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2001110120A (en) | MODIFIED SIGNAL PEPTIDE ENTEROTOXIN-II E. COLI AND MICROORGANISM EXPRESSING THE Fusion PROTEIN OF THE MENTIONED PEPTIDE WITH A HETEROLOGICAL PROTEIN | |
| Rand-Weaver et al. | Isolation and characterization of somatolactin, a new protein related to growth hormone and prolactin from Atlantic cod (Gadus morhua) pituitary glands | |
| RU2198179C2 (en) | Modified signal peptide of escherichia coli enterotoxin-ii and microorganism expressing fusion protein of mentioned peptide with heterological protein | |
| RU2109749C1 (en) | Insulin analog showing capability to decrease blood glucose content | |
| CA2033176C (en) | Growth hormone fusion proteins | |
| CN1807456B (en) | Recombinant human parathormone PTH1-34 preparation method | |
| NO965411L (en) | N-terminally extended proteins expressed in yeast | |
| JP4624495B2 (en) | Production of human insulin | |
| IE914347A1 (en) | Fusion polypeptides | |
| RU2002103159A (en) | MODIFIED COLONY STIMULATING HUMAN GRANULOCYTES FACTOR AND METHOD FOR ITS PRODUCTION, DNA, EXPRESSING VECTOR | |
| EP0510018A1 (en) | Lipoprotein signal peptide fused to antigenic polypeptides | |
| US5218093A (en) | EGF variants and pharmaceutical use thereof | |
| IE52781B1 (en) | Human proinsulin and preproinsulin genes | |
| US5399490A (en) | Vector to produce biologically important peptides | |
| Heath et al. | (ACB) human proinsulin, a novel insulin agonist and intermediate in the synthesis of biosynthetic human insulin. | |
| RU2144957C1 (en) | Recombinant plasmid dna ppins07 encoding fused polypeptide containing human proinsulin and strain of bacterium escherichia coli - producer of fused polypeptide containing human proinsulin | |
| KR100659671B1 (en) | Process for Producing Recombinant Insulin from Novel Fused Protein | |
| ES2242969T3 (en) | VECTOR FOR THE EXPRESSION OF PROTEINS WITH N-TERMINAL PROLONGATION IN LIFTING CELLS. | |
| JPH0816120B2 (en) | Hybrid polypeptide containing growth hormone releasing factor | |
| CA2057761A1 (en) | Protective plasmodium falciparum hybrid proteins which contain part-sequences of the malaria antigens hrpii and serp, the preparation and use thereof | |
| KR850006703A (en) | Method for preparing recombinant DNA expression vector | |
| EP0192743A1 (en) | Modified insulin precursors products and processes | |
| JP2003079379A (en) | Dna for achieving high expression of growth hormone and use thereof | |
| EP1016723A1 (en) | Recombinant synthesis of beta-Lipotropin and other peptides | |
| CA2034385A1 (en) | Vector to produce biologically important peptides |